DT
ACAD icon

Diversified Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Diversified Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
46,194
+1,352
+3% +$29.7K 0.02% 450
2026
Q1 		$998K Buy
44,842
+5,022
+13% +$120K 0.02% 461
2025
Q4 		$1.06M Buy
39,820
+1,942
+5% +$46.4K 0.02% 420
2025
Q3 		$808K Buy
37,878
+1,907
+5% +$45.1K 0.02% 472
2025
Q2 		$776K Hold
35,971
– – 0.02% 449
2025
Q1 		$597K Buy
35,971
+197
+0.6% +$3.58K 0.01% 519
2024
Q4 		$656K Buy
35,774
+3,187
+10% +$51.4K 0.02% 508
2024
Q3 		$501K Buy
32,587
+42
+0.1% +$701 0.01% 583
2024
Q2 		$529K Buy
32,545
+1,680
+5% +$27.1K 0.01% 528
2024
Q1 		$571K Buy
30,865
+1,826
+6% +$45.2K 0.02% 476
2023
Q4 		$909K Sell
29,039
-571
-2% -$13.6K 0.03% 316
2023
Q3 		$617K Buy
29,610
+2,442
+9% +$66.3K 0.02% 386
2023
Q2 		$651K Sell
27,168
-5,089
-16% -$113K 0.02% 385
2023
Q1 		$607K Buy
32,257
+6,411
+25% +$122K 0.02% 397
2022
Q4 		$411K Sell
25,846
-478
-2% -$7.47K 0.02% 485
2022
Q3 		$431K Buy
26,324
+15
+0.1% +$243 0.02% 437
2022
Q2 		$371K Buy
26,309
+5,464
+26% +$102K 0.02% 500
2022
Q1 		$505K Sell
20,845
-487
-2% -$11.8K 0.02% 443
2021
Q4 		$498K Sell
21,332
-2,196
-9% -$44.2K 0.02% 461
2021
Q3 		$391K Buy
23,528
+6,485
+38% +$125K 0.01% 484
2021
Q2 		$416K Buy
+17,043
New +$385K 0.02% 456
2015
Q1 		– Sell
-8,136
Closed -$258K – 492
2014
Q4 		$258K Buy
+8,136
New +$231K 0.02% 443
2014
Q2 		$477K Buy
+21,131
New +$441K 0.04% 384
2013
Q4 		$948K Sell
37,920
-3,975
-9% -$93.8K 0.1% 210
2013
Q3 		$1.15M Sell
41,895
-13,750
-25% -$287K 0.12% 177
2013
Q2 		$1.01M Buy
+55,645
New +$766K 0.12% 172

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Diversified Trust's ACAD Position: Q2 2026 in Review

Diversified Trust increased its Acadia Pharmaceuticals (ACAD) stake by 3% in Q2 2026, buying an estimated $29.7K and bringing the position to 46,194 shares worth $1.17M. The position accounts for 0.02% of the portfolio, ranked #450.

Diversified Trust first reported a position in ACAD in Q2 2013 and has held it in 26 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Diversified Trust held 46,194 shares of Acadia Pharmaceuticals worth $1.17M as of Q2 2026.
  • Diversified Trust bought 1,352 Acadia Pharmaceuticals shares in Q2 2026, an estimated $29.7K.
  • Acadia Pharmaceuticals made up 0.02% of Diversified Trust's portfolio in Q2 2026, its #450 holding.
  • Diversified Trust first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Diversified Trust's 13F filing for Q2 2026, filed 17 Jul 2026.